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Abstract This study was aimed at evaluation of changes
in activities of selected antioxidant enzymes (superoxide
dismutase, catalase, glutathione peroxidase, and glutathione
reductase) and contents of key nonenzymatic antioxidants
(glutathione, protein thiol groups, and a- and c-tocopherols)
intheleftheartventricleofyoungmaleWistarratssubjected
to endurance training (treadmill running, 1 h daily, 5 days a
week, for 6 weeks) or/and testosterone propionate treatment
(8 or 80 mg/kg body weight, intramuscularly, once a week,
for 6 weeks) during adolescence. The training alone
increased the activities of key antioxidant enzymes, but
lowered the pool of nonenzymatic antioxidants and
enhanced myocardial oxidative stress as evidenced by ele-
vationofthelipidperoxidationbiomarkermalondialdehyde.
Thelower-dosetestosteronetreatmentshowedmixedeffects
on the individual components of the antioxidant defense
system, but markedly enhanced lipid peroxidation. The
higher-dose testosterone treatment decreased the activities
of the antioxidant enzymes, lowered the contents of the
nonenzymatic antioxidants, except for that of c-tocopherol,
reversed the effect of endurance training on the antioxidant
enzymes activities, and enhanced lipid peroxidation more
than the lower-dose treatment. These data demonstrate the
potential risk to cardiac health from exogenous androgen
use, either alone or in combination with endurance training,
in adolescents.
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Introduction
The heart is characterized by one of the highest resting
oxygen consumption rates among all body organs. High
myocardial oxygen consumption, which is elevated in
response to exercise [1], may result in enhanced production
of reactive oxygen species (ROS) and impairment of the
oxidant–antioxidant balance [2]. Indeed, increased gener-
ation of ROS is detectable in rat myocardium during acute
exercise [3]. The excess ROS are disposed of quickly by
the cellular antioxidant defense systems consisted of a
number of antioxidant enzymes, including (but not limited
to) superoxide dismutase (SOD; EC 1.15.1.1), catalase
(CAT; EC 1.11.1.6), glutathione peroxidase (GPX; EC
1.11.1.9), and glutathione reductase (GR; EC 1.6.4.2), and
nonenzymatic antioxidants, such as reduced glutathione
(GSH) and a- and c-tocopherols. Electrically induced
tachycardia, which imitates cardiac effects of exercise,
acutely decreases the activities of the antioxidant enzymes
in the left heart ventricle (LV) in the rat [4], whereas the
reports on the effects of exercise training on enzymatic and
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[5–7]. Notably, there is no data on such effects in adolescents.
Myocardium is a sex steroid-sensitive tissue in that it
expresses receptors for both androgens and estrogens [8, 9].
Some studies suggest that abuse of androgenic steroids
causes adverse cardiovascular effects (e.g. LV hypertro-
phy, hypertension, diastolic dysfunction, and cardiac fail-
ure) [8, 10, 11]. However, other reports suggest that
testosterone improves myocardial lipid metabolism [12]
and may act as a cardioprotectant and coronary vasodilator
with effects comparable to those of conventional anti-
ischemic drugs [13, 14]. It is also not clear whether
androgens improve or worsen heart antioxidant status. For
instance, androgens decrease activities of heart antioxidant
enzymes in adult male rats [15]. On the other hand,
orchidectomy markedly decreases LV activities of antiox-
idant enzymes in the rat [14, 16], while testosterone
replacement reverses the deﬁcit in tissue antioxidant
capacity and substantially improves the recovery of cardiac
work after ischemia/reperfusion in vitro [14].
Whereas exercise training is often combined with ana-
bolic–androgenic steroid (AAS) use in real life (see [10,
11, 17–19]), attempts to dissect the response of the myo-
cardial antioxidant system to such combination have not
given clear-cut results. Moreover, there is no data on such
effects in adolescents, in whom these phenomena may be
affected by the ongoing somatic growth and the still-
developing pattern of sex steroids’ production and secre-
tion. Importantly, adolescence is the period that associates
with increased interest of young people, particularly boys,
in strength and/or endurance sports, or simply in body-
building. Their wish to succeed in such activities is often
fulﬁlled by combined use of the most appropriate physical
training and illegal use/abuse of AAS [10, 18, 19]. The aim
of this study was to analyze the effects of endurance
training and chronic androgen treatment of adolescent male
Wistar rats on the capacity of both enzymatic and nonen-
zymatic antioxidant defense systems in the LV.
Materials and Methods
Animals
Adolescent (5–6 weeks old) male Wistar rats of 100–120 g
body weight (BW), from the stock of Mossakowski
Medical Research Center (Warsaw, Poland), were used for
the study. The rats were housed four to ﬁve per cage, at
12-h light/12-h dark cycle (lights on at 7:00 a.m.), 22–24 C
ambient temperature and 45–65% relative humidity, and
were allowed standard pellet rat chow and tap water
ad libitum. Before the start of the experiment, all rats were
run-tested on a motorized rodent treadmill (3 9 5 min,
with 15-min breaks) for three successive days to habituate
them to the training environment and to eliminate rats
unwilling to run. The selected rats were randomized
between the following groups: (1) untrained controls (UTr,
n = 8); (2) untrained rats receiving 8 mg/kgBW of testos-
terone propionate (TP) weekly (UTr ? TP8, n = 8); (3)
untrained rats receiving 80 mg/kgBW of TP weekly
(UTr ? TP80, n = 8); (4) endurance-trained TP-untreated
rats (Tr, n = 9); (5) endurance-trained rats receiving 8 mg/
kgBW of TP weekly (Tr ? TP8, n = 8); and (6) endurance-
trained animals receiving 80 mg/kgBW of TP weekly
(Tr ? TP80, n = 9).
Hormonal Treatment
Stock TP solution (Testosteronum propionicum; Jelfa,
Poland) was diluted with sesame oil as needed and injected
intramuscularly once a week for 6 weeks, alternatingly
into the right and left hindlimb. TP-untreated rats were
given the same volume of the oil according to the same
schedule. Our choice of the lower TP dosage used was
based on the following facts: (1) a single TP dose of
8 mg/kgBW is sufﬁcient to restore physiological levels of
serum testosterone for about 1 week in castrated sedentary
young adult male Wistar rats [12, 16], while it almost
doubles circulating blood testosterone levels in their intact
counterparts (Langfort et al., unpublished data), and (2) it
approximated well the AAS dosage typically used by
athletes/bodybuilders [11, 17, 20]. The higher TP dosage
employed (80 mg/kgBW/week) was chosen to roughly
match the maximum reported AAS dosage [18]. The study
protocol was approved by the First Warsaw Ethical
Committee for Animal Experiments of the Polish Acad-
emy of Sciences, Warsaw, Poland (Certiﬁcate of approval
No. 251).
Endurance Training
The rats scheduled for endurance training were exercised on
a rodent treadmill (at 0  inclination) 5 days a week, for
6 weeks. The treadmill speed was 16 m/min during the ﬁrst
week, was increased by 4 m/min weekly over the next
3 weeks, and was kept at 28 m/min for the remaining
training sessions. The session duration started each week at
40 min/day and was increased by 5 min daily during the
ﬁrst 4 weeks; during the last 2 weeks, the rats ran for 1 h
daily. Two days after completion of the training, the rats
were euthanized by decapitation. Trunk blood was col-
lected, allowed to clot at room temperature, and spun to
obtain serum for hormone assays. The chest was opened
instantly, and the heart was perfused with the Krebs–
Henseleit buffer supplemented with glucose (10 mM),
immediately excised and weighed, and the LV was
Cardiovasc Toxicol (2011) 11:118–127 119
123separated, weighed, and cut into pieces that were snap-
frozen in liquid nitrogen and stored at -80 C until analysis.
Analytical Procedures
LV samples were homogenized in ice-cold buffers
according to the instructions provided by the manufacturer
of diagnostic kits, or in ice-cold 0.1 M phosphate-buffered
saline pH 7.0 (1:5 w/v), using an Ultra-Turrax T8
homogenizer (IKA Labortechnik, Staufen, Germany). The
homogenates were either used immediately for the deter-
mination of reduced glutathione (GSH), a- and c-toc-
opherols and malondialdehyde (MDA) or spun at
4,0009g (4 C) for 15 min to obtain supernatants for
quantiﬁcation of enzyme activities and protein thiols (-SH).
CAT activity and the contents of tocopherols and protein
thiols were assessed as described previously [4, 16]. The
activities of SOD, GPX and GR, and GSH content were
measured using BIOXYTECH kits SOD-525, GPX-340,
GR-340, and GSH-400 (OXIS International Inc., Portland,
OR, USA) according to the manufacturer’s instructions.
Serum total testosterone (TT) was determined with a
radioimmunoassay kit (Testosterone RIA, DSL-4100,
Diagnostic System Laboratories Inc., Webster, TX, USA),
and serum-free testosterone (FT) was measured using a
coated-tube radioimmunoassay (KIPI19000, DIASource
Immunoassays S.A., Belgium). Serum 17b-estradiol (E2)
level was quantiﬁed using Elecsys Estradiol electrochem-
iluminescence kit (Roche, Mannheim, Germany). Total
protein content was determined by the 2,20-bicinchoninic
acid method using Sigma Protein Assay Kit BCA1.
Statistics
All data are presented as means ± SD. A two-way
ANOVA with endurance training and TP treatment as the
main factors, followed, when appropriate, by the Tukey
post hoc test, was used to test the signiﬁcance of between-
group differences. To assess possible associations between
variables, Spearman’s rank order correlation (except when
speciﬁed otherwise) coefﬁcients were calculated. In all
cases, a P\0.05 was considered signiﬁcant. All statistical
analyses were performed using Statistica 7.1 software
(StatSoft, Tulsa, OK, USA).
Results
Serum Sex Hormone Levels
TP treatment signiﬁcantly and dose dependently elevated
serum TT and FT levels both in sedentary (untrained) and
in endurance-trained rats. Rats given the higher TP dose
compared to the sedentary controls showed, irrespective of
their training status, about 18-fold and 44-fold higher TT
and FT levels, respectively. There was a strong positive
correlation between TT and FT levels and a moderate
correlation between TT and E2 levels. Two-way ANOVA
revealed signiﬁcant effects of TP treatment, no signiﬁcant
effect of endurance training, and signiﬁcant training 9 TP
treatment interaction effects on TT and FT levels. E2 level
was only marginally affected by the TP treatment and
endurance training (Table 1).
Body and Heart Weights
Body weight was signiﬁcantly lower in endurance-trained
TP-untreated rats than in their sedentary counterparts and
tended to be lower in animals receiving TP. Two-way
ANOVA yielded signiﬁcant effects of both endurance
training and TP treatment and a signiﬁcant interaction
between these factors’ effects on BW. Body weight showed
signiﬁcant negative correlation with serum TT level,
whereas the correlation between heart weight (HW) and
serum TT level did not reach signiﬁcance. HW was sig-
niﬁcantly increased by TP treatment but not by endurance
training. Heart-to-body weight ratio (HW/BW) positively
correlated with serum TT and reached the highest level in
the endurance-trained rats given the high-dose TP treat-
ment (Table 1).
Lipid Peroxidation
Endurance training only moderately elevated LV MDA
content, while TP treatment markedly elevated it both in
trained and in sedentary rats at both doses employed. There
was no signiﬁcant interaction between these factors’ effects
on LV MDA content. Notably, there was a strong positive
correlation between LV MDA content and serum TT level
(see Table 1) and between LV MDA content and serum FT
level (R = 0.74, P\10
-6).
Left Ventricle Antioxidant Enzymes’ Activities
and Nonenzymatic Antioxidants’ Contents
SOD and CAT activities were signiﬁcantly higher in the
endurance-trained TP-untreated rats than in their sedentary
counterparts; no similar differences were found between
the respective GPX and GR activities. TP-treated rats,
particularly those receiving the higher TP dose, showed
markedly lowered activities of all antioxidant enzymes
studied (Table 2). There was a strong negative correlation
between SOD and CAT activity or serum FT (R =- 0.77,
P\10
-6 and R =- 0.63, P\10
-5, respectively) and TT
levels, whereas the correlations between GPX or GR
activity and FT (R =- 0.63, P\10
-4, and R =- 0.54,
120 Cardiovasc Toxicol (2011) 11:118–127
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-3, respectively) or serum TT level (see Table 2)
were somewhat weaker.
The endurance-trained rats compared to their untrained
counterparts showed lower LV contents of all nonenzy-
matic antioxidants studied (Table 3). TP treatment resulted
in signiﬁcant decreases in the contents of a-tocopherol and
protein thiols; a marked tendency for such effect was also
apparent in the LV GSH content. Notably, a-tocopherol
level correlated negatively with both serum FT (Spearman
rank order correlation test: R =- 0.40, P = 0.02) and TT
level. In contrast, c-tocopherol content tended toward
higher levels in both sedentary and trained groups of ani-
mals receiving TP and showed a signiﬁcant, while mod-
erate, positive correlation with serum TT level (see
Table 3), but not with FT level (P = 0.13).
Discussion
The main ﬁndings of the present study are that (1) endur-
ance training by itself increases the activity of two key
components of heart enzymatic antioxidant system, namely
SOD and CAT, but decreases the capacity of heart non-
enzymatic antioxidant system and increases LV lipid per-
oxidation; (2) high-dose TP treatment decreases the
capacity of both these antioxidant systems by itself,
reverses the beneﬁcial effect of endurance training on SOD
and CAT activities, and potentiates myocardial lipid per-
oxidation. Whereas the effects of exercise training and
androgens on heart antioxidant systems have been studied
before, this study, to the best of our knowledge, is the ﬁrst
to investigate the effects of these factors in adolescent
subjects. This issue is of considerable importance because
of the well-known AAS abuse by adolescent bodybuilders
and athletes and the emergence of the related spectrum of
adverse side effects including a number of cardiac and
cardiovascular complications leading eventually to death in
some cases [10, 11, 17, 19–22].
While AAS can cause detrimental shifts in serum lipid
proﬁle, AAS abuse-related cardiac deaths are not neces-
sarily related to coronary thrombosis or atherosclerosis [10,
22, 23], but may be caused also by a variety of pathological
phenomena related to apoptosis [24]. The lower TP dose
used in this study markedly elevated myocardial MDA in
untrained rats, implying a substantial increase in oxidative
stress. This may look surprising, as there was no concurrent
decrease in major antioxidant enzyme activities and most
nonenzymatic antioxidants studied. However, it is known
that testosterone (serum levels of which positively corre-
lated with LV MDA content in this study) elevates the
activity of hormone-sensitive lipase and thereby stimulates
lipolysis in rat cardiomyocytes [12]. This improves long-
chain fatty acids availability for ATP synthesis, which in
turn elevates oxygen utilization and thus enhances gener-
ation of ROS. The reported testosterone-induced increase
in adipose tissue lipolysis [25] could have contributed also
to the decreased BW of TP-treated rats in this study.
TP treatment substantially elevated both serum TT and
FT in our rats, but the respective relative increases were
much larger for FT (see Table 1). The traditional view
holds that only FT represents biologically active testos-
terone. However, there was a high positive correlation
between serum TT and FT levels in this study, and the
correlation coefﬁcients between the other indices measured
and FT or TT level were, pair wise, remarkably similar (not
shown), except that there was no signiﬁcant correlation
between serum FT and E2 levels (R = 0.22, P = 0.18).
Thus, our data support the view that serum TT accurately
reﬂects biologically active testosterone in adolescent rats
[10, 26]. Interestingly, serum TT levels in the rats treated
with the lower TP dose were, 9 days after the last dose,
several times higher than those found during the ﬁrst week
following the injection of the same TP dose to naı ¨ve young
adult male rats (Langfort et al., unpublished data). This
shows extensive buildup of serum testosterone with weekly
TP doses, which is in clear contrast with the need for
administration of TP at 2- to 3-day intervals in humans
with the aim of attaining reasonably stable TT levels.
Evidence from animal studies indicates that, compared
with other aerobic tissues, the heart has moderate levels of
antioxidant enzymes and thus rather limited ability to
remove ROS [2]. Hence, it is possible that the LV anti-
oxidant enzyme system was unable to inactivate the
excessive ROS formation consequential to supraphysio-
logical testosterone doses used in our study. However,
signiﬁcant decreases in the antioxidant enzymes’ activities
could have contributed to increased oxidative stress in rats
given the higher TP dose treatment. It is well documented
that SOD is irreversibly inactivated (by up to 50%) by its
product hydrogen peroxide in a concentration-dependent
manner [27]. Besides, CAT, a heme enzyme, is rapidly
inhibited by superoxide anions (O2
•-) due to a reversible
reaction of O2
•- radicals with native enzyme which
involves a reduction of the ferric (Fe
3?) center to oxyfer-
rous heme (Fe
2?)_O2 [28]. Whereas consequences of
increased oxidative stress in the model used in our study
are not clear, it has been shown that such stress can induce
apoptosis in rat ventricular myocytes in vitro [29].
Endurance training employing a protocol closely related to
this used in our study has been shown to attenuate this
effect by SOD- and Hsp70-mediated pathways in rats [30].
However, superoxide radical is not the only ROS that is
involved in apoptosis, and different ROS may use distinct
apoptotic pathways [29].
Our training protocol is known to shift anaerobic
threshold to higher exercise intensity [31], and its
124 Cardiovasc Toxicol (2011) 11:118–127
123effectiveness is additionally evidenced by the signiﬁcant
increase in HW/BW ratio in TP-untreated endurance-
trained rats in this study. The shift in anaerobic threshold is
associated with increased oxidative capacity and reliance
of oxidative muscles on fat metabolism and presumably
with enhanced ROS formation that may lead to enhanced
lipid peroxidation [32].
The published reports on changes in lipid peroxidation
induced by chronic exercise are equivocal. For instance,
signiﬁcant increases in MDA content in heart tissue of
chronically exercised rats were reported by some
researchers [33], whereas no changes were found in
another study [3]. Similarly, the literature is ambiguous
regarding which myocardial antioxidants are elevated after
exercise training [7, 15, 34, 35]. Endurance training has
been shown to increase the activities of antioxidant
enzymes, particularly of SOD and CAT, in adult rats. The
most robust responses to endurance training revealed in the
present study were the increases in LV activities of SOD
(the enzyme considered essential for protection against
ROS) and CAT (the enzyme involved in removal of
hydrogen peroxide produced by SOD) in TP-untreated rats.
This apparent enhancement of enzymatic antioxidant
defense was, however, associated with a signiﬁcant nega-
tive impact of the training on all nonenzymatic antioxidants
studied, and thus it could not prevent the enhancement of
lipid peroxidation evidenced by the signiﬁcant effect of the
training on LV MDA content. Again, this observation is in
agreement with the aforementioned moderate ability of
heart antioxidant systems for neutralizing ROS [2].
Two-way ANOVA of enzyme activities’ data revealed
signiﬁcant interactions between endurance training and TP
treatment effects on key components of the enzymatic
antioxidant defenses, i.e., the SOD and CAT activities.
This indicates that combining endurance training with the
intake of high androgen doses in adolescent subjects
weakens heart antioxidant defenses and may potentiate risk
to cardiac health. On the other hand, there was no statis-
tically signiﬁcant interaction between endurance training
and TP treatment effects on either the LV MDA or LV
nonenzymatic antioxidants’ levels. This result shows
additivity of these manipulations and suggests no beneﬁt,
in terms of cardioprotection, from endurance training when
combined with AAS use. In line with our observations, it
has been shown that nandrolone decanoate treatment
interferes with cardiac renin-angiotensin system and
impairs the beneﬁcial effect of another type of aerobic
training (swimming) in young adult rats [36].
The heart is a target organ for estrogens that are sup-
posed to be cardioprotective [37]. As suggested by positive,
while moderate, correlation between serum testosterone
and estradiol levels, a fraction of the injected TP was
converted to estradiol in our rats. However, serum E2 level
was but marginally affected by the TP treatment (see
Table 1) and did not positively correlate with any studied
component of the LV antioxidant defense system. Con-
versely, it showed signiﬁcant negative correlations with LV
SOD, CAT and GR activities, and with LV a-tocopherol
level, with correlation coefﬁcients ranging from -0.32 to
-0.45. All these coefﬁcients were considerably lower than
those for serum TT level (see Table 2), which indicates
that they merely reﬂected substrate–product relationship
between testosterone and E2. These data are in agreement
with earlier reports that showed no major effect of exog-
enous testosterone on circulating E2 level in male rodents
[14] and suggest no cardioprotective effect from systemic
testosterone aromatization.
Notably, there was no signiﬁcant correlation between
serum E2 level and LV c-tocopherol content, whereas the
latter correlated positively with serum TT level. ANOVA
yielded signiﬁcant decreasing effect on this antioxidant
from endurance training and an opposing effect from TP
treatment. The latter ﬁnding may be of importance in light
of reports showing that c-tocopherol has potent anti-
inﬂammatory properties [38] and may be an effective
cardioprotectant [39]. It is not clear whether the elevation
in LV c-tocopherol was driven by its mobilization from
peripheral stores in response to oxidant attack, as previ-
ously reported for other localizations [40, 41], or resulted
from the known inverse relationship between c- and a-
tocopherol [42]. However, the substantial TP treatment-
related elevation in LV MDA observed in the present study
indicated that the increased c-tocopherol content was
insufﬁcient to counteract the enhancement of myocardial
oxidative stress induced by TP treatment.
To summarize, this study shows that in adolescent male
rats: (1) all potentially beneﬁcial effects of endurance
training on the enzymatic components of the antioxidant
defense system in the heart left ventricle are reversed by
chronic high-dose testosterone propionate treatment and
(2) none of the potentially detrimental effects of the
training on the left ventricular antioxidant barrier are
considerably counteracted by this treatment. These results
imply that anabolic androgen use among adolescents, either
alone or in combination with endurance training, may
elevate oxidative stress-related risk to cardiac health.
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